Post by
cheetio on Sep 10, 2015 9:57am
Feast track
David Miller, co-founder and CEO of Seattle-based Biotech Stock ....."They make it look like the FDA only chooses for Fast Track those drugs that are important and have a good chance, and that's just not the case because the FDA will Fast Track most anything.................. Reni Benjamin, senior biotech analyst with Rodman & Renshaw, a New York investment banking firm," Benjamin said. "A Fast Track designation, frankly, is noise and an opportunity to take some profit." https://blog.cleveland.com/pdworld/2007/12/_a_decade_ago_the.html
Comment by
DamnYankees on Sep 10, 2015 11:03am
Good Find Chet, these fast track trials are far more common than people think. I'm a buyer if we can drop another 30-35% which seems like a lock with no confidence, no interest and no buyers. Eventually a competent buyer for the whole operation will step in.
Comment by
somweyungguy on Sep 10, 2015 3:00pm
Isn't a feast track when you sit on data for 7 years, let drama after drama play out with full bullboard play by play and print 200MM additional shares without any promotion? I'd call that a feast track.